{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:33:36Z","timestamp":1774020816343,"version":"3.50.1"},"reference-count":24,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NDT"],"DOI":"10.2147\/ndt.s562499","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:20:11Z","timestamp":1774016411000},"page":"1-11","source":"Crossref","is-referenced-by-count":0,"title":["The Clinically Meaningful Score Difference and Meaningful Score Regions in Positive and Negative Syndrome Scale Total Score from Post Hoc Analyses of a Phase 3 Pivotal Clinical Trial of Transdermal Asenapine in Patients with Schizophrenia"],"prefix":"10.2147","volume":"Volume 22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-9266","authenticated-orcid":true,"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e1l","family":"Czobor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Komaroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahwish","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Terahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mcna.2022.05.005","volume":"107","author":"Faden","year":"2023","journal-title":"Med Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s10803-019-04326-0","volume":"50","author":"Cook","year":"2020","journal-title":"J Autism Dev Disord"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/schbul\/sbj041","volume":"32","author":"Gur","year":"2006","journal-title":"Schizophr Bull"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"20m13602","DOI":"10.4088\/JCP.20m13795","volume":"82","author":"Citrome","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"ref6","unstructured":"SECUADO\u00ae (Asenapine) Transdermal System [Prescribing Information]. Miami, FL: Noven Therapeutics, LLC; 2025."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14355","volume":"83","author":"Citrome","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2147\/NDT.S439712","volume":"20","author":"Citrome","year":"2024","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","volume":"119","author":"Leucht","year":"2009","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"816339","DOI":"10.3389\/fpsyt.2022.816339","volume":"13","author":"Czobor","year":"2022","journal-title":"Front Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.64719\/pb.4069","volume":"44","author":"Suzuki","year":"2011","journal-title":"Psychopharmacol Bull"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41386-019-0363-2","volume":"44","author":"Leucht","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"B16","DOI":"10.1016\/j.clinthera.2011.11.016","volume":"33","author":"Correll","year":"2011","journal-title":"Clin Ther"},{"key":"ref14","unstructured":"US Food and Drug Administration (FDA). Patient-focused drug development guidance public workshop: methods to identify what is important to patients & select, develop or modifyfit-for-purpose clinical outcomes assessments. 2018. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/patient-focused-drug-development-guidance-methods-identify-what-important-patients-and-select. Accessed May 8, 2024."},{"key":"ref15","unstructured":"US Food and Drug Administration (FDA). Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making: guidance for industry, food and drug administration staff, and other stakeholders. 2023. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory. Accessed May 8, 2024."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/schbul\/sbp124","volume":"36","author":"Obermeier","year":"2010","journal-title":"Schizophr Bull"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/01.jcp.0000218407.10362.6e","volume":"26","author":"Rabinowitz","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1176\/ajp.2006.163.4.743","volume":"163","author":"Emsley","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000205518","volume":"59","author":"Lee","year":"2009","journal-title":"Neuropsychobiology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.schres.2009.05.002","volume":"113","author":"Sacchetti","year":"2009","journal-title":"Schizophr Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.schres.2013.06.023","volume":"150","author":"Rabinowitz","year":"2013","journal-title":"Schizophr Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2147\/NDT.S503494","volume":"21","author":"Citrome","year":"2025","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref24","first-page":"14","volume":"20","author":"Citrome","year":"2023","journal-title":"Innov Clin Neurosci"}],"container-title":["Neuropsychiatric Disease and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/113258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/113258","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:20:13Z","timestamp":1774016413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/the-clinically-meaningful-score-difference-and-meaningful-score-region-peer-reviewed-fulltext-article-NDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"URL":"https:\/\/doi.org\/10.2147\/ndt.s562499","relation":{},"ISSN":["1178-2021"],"issn-type":[{"value":"1178-2021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}